Generation of FMC63 scFv specific anti-idiotype antibodies for quality control of anti-CD19 CAR T cell trials
WO2017015783A1 - Humanized anti-cd19 antibody and use thereof - Google Patents
CAT19 and FMC63 share similar biophysical properties, with the... | Download Scientific Diagram
A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expr
IJMS | Free Full-Text | Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions - ScienceDirect
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions - ScienceDirect
CAR-T design: Elements and their synergistic function - eBioMedicine
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
A Fast and Sensitive Luciferase-based Assay for Antibody Engineering and Design of Chimeric Antigen Receptors | Scientific Reports
Frontiers | The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
Addgene: pSLCAR-CD19-28z
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma | Nature Medicine
![Chimeric Antigen Receptor (car) Comprising A Cd19-binding Domain Pule; Martin ; et al. [UCL BUSINESS PLC]](https://uspto.report/patent/app/20200140544/US20200140544A1-20200507-D00001.png "Chimeric Antigen Receptor (car) Comprising A Cd19-binding Domain Pule; Martin ; et al. [UCL BUSINESS PLC]")
Chimeric Antigen Receptor (car) Comprising A Cd19-binding Domain Pule; Martin ; et al. [UCL BUSINESS PLC]
Cancers | Free Full-Text | The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
Apoptotic cells therapy for the prevention of cytokine release syndrome (CRS) in CAR T-cell therapy
Leukaemic response and relapse patterns associated with SJ25C1 and... | Download Scientific Diagram
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients | Nature Communications
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines | Journal for ImmunoTherapy of Cancer
Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials | PLOS ONE
RCSB PDB - 7URV: FMC63 scFv in complex with soluble CD19
